Anzeige
Mehr »
Login
Sonntag, 13.10.2024 Börsentäglich über 12.000 News von 676 internationalen Medien
Eine weltweite Kupferknappheit zeichnet sich ab: Warum Gladiator Metals (WKN: A3D6HK) die Antwort sein könnte
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 570796 | ISIN: NO0003096208 | Ticker-Symbol: Z1L
Tradegate
11.10.24
16:07 Uhr
4,452 Euro
+0,002
+0,04 %
1-Jahres-Chart
LEROY SEAFOOD GROUP ASA Chart 1 Jahr
5-Tage-Chart
LEROY SEAFOOD GROUP ASA 5-Tage-Chart
RealtimeGeldBriefZeit
4,4144,46212.10.
4,4324,46611.10.
GlobeNewswire (Europe)
176 Leser
Artikel bewerten:
(1)

Lerøy Seafood Group ASA: Continued progress in biological performance

PROGRESS IN BIOLOGICAL PERFORMANCE CONTINUES

Lerøy Seafood Group ASA today reports a consolidated operational EBIT of NOK 906 million for the second quarter of 2024.

CEO Henning Beltestad comments: "The positive trend in biological performance has continued into the second quarter, and we are performing well in a quarter characterized by declining salmon prices. The number of lice treatments has been significantly reduced, and growth and survival rates have substantially increased compared to the average over the past five years.

Almost five years ago, we launched an extensive project to explore new technologies aimed at addressing one of the industry's biggest challenges: the presence of sea lice and the related treatments that negatively affect fish welfare. In August 2024, we harvested our first salmon from submerged cages. This innovative technology is showing very promising results, and we believe it will be an important growth driver for Lerøy going forward," says Beltestad.

Scottish Seafarms also delivered significant improvements in biology, resulting in a considerable increase in profit compared to last year.

VAP S&D ACHIEVES RECORD HIGH EARNINGS

The segment for value-added processing, sales & distribution (VAP S&D) reported an operational EBIT of NOK 217 million in Q2 2024. "The positive development in the segment continues. This is driven by operational improvements and increased utilization of our integrated value chain," says Beltestad.

"We are a significant food producer, well-positioned, and we feel a great responsibility to contribute to increased seafood consumption in line with the updated dietary guidelines from the Norwegian Directorate of Health, which confirm that one should eat more seafood," he continues.

CHALLENGES IN WILD CATCH DUE TO REDUCED QUOTAS

The Wild Catch segment reported an operational EBIT of NOK -4 million, which is significantly lower than the same quarter last year. "The outlook for wild catch is very challenging due to significant quota reductions in recent years. The quota advice for 2025 indicates further cuts. This development is undoubtedly challenging for this part of our business," points out Beltestad.

ACHIEVING STRATEGIC GOALS THROUGH OPERATIONAL EXCELLENCE

"Lower salmon prices affected the market in the second quarter, but we are optimistic about the long-term outlook. We are on track to achieve our ambitious 2025 goals for both Farming and VAP S&D. We are highly focused on improving roe and smolt quality, implementing new farming technology, and optimizing processes. We are also seeing increasing demand for an integrated value chain with a strong sustainability profile, and we see significant potential to increase earnings in our European downstream operations," concludes Beltestad.

For inquiries, please contact CEO Henning Beltestad or CFO Sjur S. Malm.


ABOUT LERØY SEAFOOD GROUP

Lerøy Seafood Group is a global seafood group headquartered in Bergen. The company's approximately 6,000 employees annually handle between 350,000 and 400,000 tons of seafood through the company's value chain, equivalent to about 5 million meals every day. The group has a vertically integrated value chain for redfish and whitefish, as well as significant third-party product activity.

The Group's values, "open, honest, responsible, and creative," are the basis for the Group's total activities, and efforts are made towards the goal of creating the world's most efficient and sustainable seafood value chain. The target for annual return on capital employed (ROCE) is 18%. The group has set ambitious sustainability goals, including a 46% reduction in greenhouse gas emissions by 2030.

To ensure food safety for the consumer, we actively work in all stages of the value chain. As a fully integrated seafood supplier, we have the opportunity to control and quality-assure our products throughout the entire value chain. This way, we can meet the seafood market's increasingly stringent requirements for traceability, food safety, product quality, cost-effectiveness, sustainability, and continuous delivery.

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.


© 2024 GlobeNewswire (Europe)
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.